TScan Therapeutics Inc
NASDAQ:TCRX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.94
9.51
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
TScan Therapeutics Inc
Income from Continuing Operations
TScan Therapeutics Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
TScan Therapeutics Inc
NASDAQ:TCRX
|
Income from Continuing Operations
-$89.2m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$5.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$113m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-36%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$4.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
-$479.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4.7B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
30%
|
|
TScan Therapeutics Inc
Glance View
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The firm's lead liquid tumor TCR-T therapy candidates include TSC-100 and TSC-101, which are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation (HCT). TSC-100 and TSC-101 targets histocompatibility antigens (HA)-1 and HA-2 antigens, respectively. TScan solid tumor product candidates include TSC-200, TSC-201, TSC-202 and TSC-203. Its TSC-200 series of product candidates are being developed to treat both HPV-positive and HPV-negative tumors. The firm's platform technologies include TargetScan, ReceptorScan and T-Integrate.
See Also
What is TScan Therapeutics Inc's Income from Continuing Operations?
Income from Continuing Operations
-89.2m
USD
Based on the financial report for Dec 31, 2023, TScan Therapeutics Inc's Income from Continuing Operations amounts to -89.2m USD.
What is TScan Therapeutics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-51%
Over the last year, the Income from Continuing Operations growth was -35%. The average annual Income from Continuing Operations growth rates for TScan Therapeutics Inc have been -51% over the past three years .
You don't have any saved screeners yet
